AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02983110 — intervention group
Intervention type: PROCEDURE
Intervention: Female Genital Tract Sampling
Description: Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
Study NCT00909402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
Study NCT00909402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
Study NCT00909402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
Study NCT02853162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ARREST-study
Description: Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
Study NCT03318471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSo4
Description: 50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
Study NCT03318471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
Study NCT03291925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective invasive angiography based on CT/CCTA imaging.
Study NCT03291925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery: Invasive angiography
Study NCT06121193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT tool
Description: PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
Study NCT06121193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control
Description: Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen Tablet
Description: 2 test acetaminophen 500 mg tablets
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen Caplet
Description: 2 commercial acetaminophen 500 mg caplets
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen Liquid-filled capsule
Description: 2 commercial ibuprofen 200 mg Liquid-filled capsules
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: 2 placebo tablets
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: 2 placebo tablets
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Caplet
Description: 2 placebo caplets
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Caplet
Description: 2 placebo caplets
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Caplet
Description: 2 placebo caplets
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Liquid-filled capsule
Description: 2 placebo Liquid-filled capsules
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Liquid-filled capsule
Description: 2 placebo Liquid-filled capsules
Study NCT02735122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Liquid-filled capsule
Description: 2 placebo Liquid-filled capsules
Study NCT01652794 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT01652794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01652794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01652794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01652794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Optional correlative studies
Study NCT03264898 — intervention group
Intervention type: DEVICE
Intervention: Fecal immunochemical test (FIT)
Description: FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
Study NCT02947230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Knowledge Translation
Description: Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
Study NCT02548897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
Study NCT02548897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
Study NCT02867930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: drug for moderate sedation in trans-esophageal echocardiography
Study NCT02867930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol(ketamine+propofol)
Description: drug for moderate sedation in trans-esophageal echocardiography
Study NCT03514771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fraxel DUAL 1550/1927
Study NCT03514771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral isotretinoin
Description: oral isotretinoin
Study NCT03514771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral valacyclovir
Description: Oral valacyclovir
Study NCT02134405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Rebamipide 100mg tid
Study NCT02134405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide
Description: Rebamipide 100mg tid
Study NCT02134405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Esomeprazole)
Description: Sugar pill manufactured to mimic Esomeprazole
Study NCT00889044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel by chewing
Description: 600 mg clopidogrel by chewing
Study NCT00889044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o
Study NCT04433507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
Study NCT04433507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
Study NCT02134405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole tablets 20mg o.d. for 8 weeks
Study NCT00778505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: closed-loop administration using bispectral index as the controller
Study NCT00778505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: closed-loop administration using bispectral index as the controller
Study NCT04936984 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Kindeva)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
Study NCT04936984 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes
Study NCT04936984 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
Study NCT00778505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: manual administration according bispectral index values
Study NCT00778505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: manual administration according bispectral index values
Study NCT03212222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peek Acuity
Description: Cell phone application for visual acuity screening
Study NCT04433507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hiatal Hernia repair
Description: Hiatal hernia repair consists in a circumferential dissection of the diaphragmatic crura to achieve an intra abdominal esophageal length of 2-3 cm. The crura will then be closed anteriorly and posteriorly using nonabsorbable sutures.
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Romosozumab
Description: Administered by subcutaneous injection QM or Q3M.
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Administered orally once a week
Study NCT03212222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Visual Screening
Description: Visual screening exam conducted in Duke University Eye Center
Study NCT04022798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise, manual therapy
Description: Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists.
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide 20 μg administered by subcutaneous injection once a day
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study NCT04022798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, manual therapy
Description: Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists.
Study NCT03148704 — intervention group
Intervention type: DRUG
Intervention: palonosetron hydrochloride capsules
Description: Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
Study NCT01138436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO Wound Ointment (MEBO)
Description: Topical application once a day
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M
Study NCT00896532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg administered by subcutaneous injection Q6M
Study NCT01138436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Application of Profore multilayer compression bandage system
Study NCT03567174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care van (ICV)
Description: Structural service delivery intervention
Study NCT01903317 — intervention group
Intervention type: OTHER
Intervention: Topical Therapy
Description: Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
Study NCT01903317 — intervention group
Intervention type: OTHER
Intervention: Phototherapy and Systemic Therapy
Description: Subjects will continue use of phototherapy (e.g. ultraviolet B \[UVB\] or ultraviolet A and psoralen \[PUVA\]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
Study NCT01903317 — intervention group
Intervention type: OTHER
Intervention: Biologic Therapy
Description: Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
Study NCT03164889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage-colony Stimulating Factor
Description: The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
Study NCT03164889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Antiviral drug for hepatitis b virus (HBV)
Study NCT03164889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Antiviral drug for hepatitis b virus (HBV)
Study NCT01472393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Description: The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
Study NCT01472393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dextrose (placebo)
Description: The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
Study NCT01263860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
Study NCT01263860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
Study NCT01263860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
Study NCT01263860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
Study NCT02554370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational programme
Description: 4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
Study NCT04061005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: CSP, which does not include electrocautery to do a polypectomy with a snare.
Study NCT04061005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot snare polypectomy
Description: HSP, which uses the electrocautery to do a polypectomy with a snare.
Study NCT04061005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic margin observation method
Description: Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
Study NCT04061005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic margin observation method
Description: Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
Study NCT06309901 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: Home exercises were applied in 3 progressive phases.~1st phase: postoperative 0-4. week, 2nd phase: 5-12. week, 3rd phase 12-15. week.~In the 1st phase, ice application, strengthening for the hip, knee and ankle, and walking exercises were applied. 90 degrees knee flexion range of movement (ROM) was targeted.~In the 2nd phase, the resistance of the strengthening exercises was increased and closed kinetic chain exercises were added. Weight bearing, step climbing and balance exercises were performed. Full ROM targeted in the knee.~In the 3rd phase, pain-free full ROM was targeted, and progressive strengthening, balance and agility exercises for sports and recreational activities were applied.
Study NCT06309901 — intervention group
Intervention type: OTHER
Intervention: Fascial Distortion Model
Description: At the beginning of the 2nd phase of the treatment, starting from the 5th week, twice a week for 4 weeks, a total of 8 sessions of FDM technique were applied.~In this study, trigger band technique was chosen to apply around the knee. Interventions were made directly to the skin in the form of medial, lateral, anterior, posterior techniques of the knee and posterior and lateral techniques of the thigh. The techniques was made after the exercises.
Study NCT06309901 — intervention group
Intervention type: OTHER
Intervention: Instrument Assisted Soft Tissue Mobilisation
Description: At the beginning of the 2nd phase of the treatment, starting from the 5th week, twice a week for 4 weeks, a total of 8 sessions of IASTM technique were applied.~In this study, the Graston technique was chosen to apply IASTM around the knee. Technique was applied with using stainless steel and ultrasound gel to around the knee, m. quadriceps, m. hamstring, iliotibial band and medial thigh. The technique was performed for at least 2 minutes in each region.
Study NCT00727961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin hydrochloride
Description: Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
Study NCT01856426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP239
Study NCT01856426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00336622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint fabricated by an OT versus an off-the-shelf splint
Description: Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises
Study NCT00336622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splint fabricated by an OT versus an off-the-shelf splint
Description: Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises
Study NCT02189941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone sustained-release
Description: Deferiprone sustained-release tablets
Study NCT02189941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone immediate-release
Description: Deferiprone immediate-release tablets